[Production of adriamycin covalent binding to monoclonal antibody OC-859 and its anti-tumor activities].

Using periodate oxidation method adriamycin was linked to monoclonal antibody OC859, and a monoclonal antibody-adriamycin (McAb ADR) conjugate was produced. The molar ratio of ADR:OC859 was 12:1. This drug-antibody conjugate still retained its cytotoxic effects and antibody activities. The cytotoxic effects of McAb-ADR conjugate on the growth of tumor cells CAOV3 was determined by microculture tetrazolium assay. It revealed that when the concentration of the McAb-ADR conjugate was 1 microM more than 50% of CAOV3 cells were inhibited. And for normal endometrial cells no more than 50% inhibition could be shown even with the concentration up to 10 microM. In vivo, the human ovarian epithelial carcinoma transplanted to nude mice was also inhibited with McAb-ADR conjugate. The above results showed that the McAb-ADR conjugate can selectively cause inhibition of tumor cells both in vivo and in vitro, and may be helpful in the treatment of ovarian epithelial carcinoma in the future.